Having completed the revamp of the NDDD program, Lupin has now created very sophisticated infrastructure, acquired cutting-edge technologies and we have built a brilliant pool of top notch talent that will create significant value going forward. The NDDD program would focus to win in the mid to longer-term by a "Quick-Win, Fail-Fast" cost-efficient development approach, differentiated by establishing a 'Efficacy Within Time' approach, while ensuring safety. Six of our programs have already progressed to a lead-to-clinical candidate phase.
In FY 2011, the group implemented a centralized corporate R&D database (Chem-Bio Office), which is critical for managing the knowledge generated within the NDDD program and is key for decision making with respect to product pipeline progression. Five leading therapeutic area experts of international repute have joined our advisory panel. We also have a strong intellectual property creation and management strategy in place; 22 patents have been filed for global coverage; and there are continuous efforts to enhance our patent portfolio.